More than 16,000 doses of Ervebo vaccine arrive in Ebola-hit DR Congo
The first of 70,000 Ervebo vaccine doses allocated for Kinshasa have arrived in the Democratic Republic of Congo, as experts warn the Ebola virus is spreading exponentially.
More than 16,000 doses of the Ervebo vaccine have arrived in the Democratic Republic of Congo, which is currently experiencing an Ebola outbreak. The shipment marks the first portion of a total of 70,000 doses allocated for the capital, Kinshasa.
Ervebo is a vaccine against the Ebola virus, used to help contain outbreaks among at-risk groups and in affected areas. The delivery to Kinshasa comes as health experts warn that the virus is spreading exponentially, pointing to a rapidly increasing number of infection cases.
Why it matters
Kinshasa is the capital of the Democratic Republic of Congo and one of the largest and most densely populated cities in Africa, meaning an Ebola outbreak there raises serious concerns about further, wider spread of the disease. The remaining doses are expected to be delivered later, allowing the vaccination campaign to expand gradually across the city.
Vaccination is regarded as one of the key tools in fighting Ebola outbreaks, as it helps protect people who have had contact with infected individuals as well as healthcare workers, who face particularly high exposure risk. The rapid spread of the virus means time is a critical factor — the sooner vaccines reach affected areas, the greater the chance of containing further transmission.
No detailed information has yet been made public about the total number of cases or the specific areas where the outbreak is most severe, but the warnings about exponential spread suggest the situation is being treated as serious.
